Cargando…

Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study

Background: Osteoarthritis (OA) is a progressive degenerative disease with an inflammatory background. Chronic myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders characterized by chronic inflammation and a tendency for connective tissue remodeling. Aim: This study aimed to investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holik, Hrvoje, Krečak, Ivan, Lucijanić, Marko, Samardžić, Ivan, Pilipac, Danijel, Vučinić Ljubičić, Ivana, Coha, Božena, Kitter Pipić, Alma, Miškić, Blaženka, Zupančić-Šalek, Silva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300951/ https://www.ncbi.nlm.nih.gov/pubmed/37374170 http://dx.doi.org/10.3390/life13061388

Ejemplares similares

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB2201: ASSOCIATION OF HIGH PLATELETCRIT WITH THROMBOTIC RISK IN POLYCYTHEMIA VERA DEPENDS ON HEMATOCRIT AND LEUKOCYTE COUNT
por: Krecak, Ivan, et al.
Publicado: (2023)

P1051: CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
por: Krečak, Ivan, et al.
Publicado: (2023)

PB2188: PROTON PUMP INHIBITORS ARE SAFE AND EFFECTIVE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA TREATED WITH LOW-DOSE ASPIRIN
por: Krecak, Ivan, et al.
Publicado: (2023)

PB2219: POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Lucijanic, Marko, et al.
Publicado: (2021)

Venous thromboembolism in Croatia – Croatian Cooperative Group for Hematologic Diseases (CROHEM) study
por: Pulanić, Dražen, et al.
Publicado: (2015)

PB2269: HUMORAL AND T-CELL RESPONSES TO SARS-COV2 VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA MANAGED IN THE COMMUNITY SETTING
por: Holik, H., et al.
Publicado: (2022)

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

Duffy‐null erythrocyte phenotype and the risk of thrombotic events in essential thrombocythemia
por: Krecak, Ivan, et al.
Publicado: (2023)

PB2194: HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME
por: Lucijanic, Marko, et al.
Publicado: (2023)

Leuconostoc sp. Meningitis in a Patient Treated with Rituximab for Mantle Cell Lymphoma
por: Holik, Hrvoje, et al.
Publicado: (2015)

PB1825: TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS MANAGED IN THE COMMUNITY SETTING IN CROATIA
por: Krecak, I., et al.
Publicado: (2022)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
por: Sertić, Zrinka, et al.
Publicado: (2022)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases
por: Aurer, Igor, et al.
Publicado: (2021)

SCROTAL THERMOGRAPHY IN THE EVALUATION OF SURGICAL OUTCOME AFTER VARICOCELE REPAIR: A CASE REPORT
por: Karlović, Krešimir, et al.
Publicado: (2022)

Comparison of IMPROVE, modified IMPROVE, IMPROVEDD, Padua and CHA2DS2-VASC risk scores for venous and arterial thrombotic events prediction in hospitalized COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

Genetic–pathologic characterization of myeloproliferative neoplasms
por: Kim, Yonggoo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tib2gt7u8iljt3o6khmt5tim0q